Drug profile · INN
fruquintinib
FRUZAQLA
fruquintinib (FRUZAQLA) is a vascular endothelial growth factor receptor inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — fruquintinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
fruquintinib (FRUZAQLA) is a vascular endothelial growth factor receptor inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Vascular endothelial growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fruquintinib?
fruquintinib (FRUZAQLA) is a vascular endothelial growth factor receptor inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fruquintinib?
FRUZAQLA is a marketed brand name for fruquintinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fruquintinib?
fruquintinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.